Skip to main content

Table 2 Cost-effectiveness results under base case assumptions for screening for HBsAg using laboratory-based assay on a simulated birth cohort of 10,000 live singleton infants

From: Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa

Strategy Number of infant HBV infectionsa (95% CI) Cost of deploying the intervention for the whole populationb (n = 10,000) in USD (95% CI) Incremental cost per infection avoided (USD)
S1 45 (29–121) 0
S2 21 (14–69) 94,571 (94,487 - 95,509) 3940 (compared to strategy S1)
S3 28 (19–76) 95,097 (94,980 - 97,244) Dominatedc (by strategy S2)
  1. a World Health Organisation (WHO) criteria for HBV elimination states an aim of 90% reduction in new chronic infection [1]
  2. b Price of TDF estimated at $2.48/month for strategies S2 and S3 [30]
  3. c S3 is dominated due to both higher costs and higher infections compared to S2
  4. CI = confidence interval